Spruce Biosciences annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Spruce Biosciences R&D Spending Growth & History (SPRB)
Spruce Biosciences's r&d spending was $19.5M for fiscal 2025.
View full Spruce Biosciences company overviewSpruce Biosciences annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $19.5M | −$26.9M | −57.94% |
| 2024 | 2024-12-31 | $46.4M | −$3.0M | −6.10% |
| 2023 | 2023-12-31 | $49.4M | $14.2M | +40.44% |
| 2022 | 2022-12-31 | $35.2M | $4.5M | +14.66% |
| 2021 | 2021-12-31 | $30.7M | $6.8M | +28.69% |
| 2020 | 2020-12-31 | $23.9M | $13.0M | +120.52% |
| 2019 | 2019-12-31 | $10.8M | — | — |
Spruce Biosciences quarterly r&d spending
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $12.2M | $11.7M | +2728.60% |
| Q1 2026 | 2026-03-31 | $7.6M | −$3.3M | −30.10% |
| Q4 2025 | 2025-12-31 | $3.2M | −$18.2M | −84.88% |
| Q3 2025 | 2025-09-30 | $5.0M | −$1.5M | −23.54% |
| Q2 2025 | 2025-06-30 | $430,000 | −$7.7M | −94.68% |
| Q1 2025 | 2025-03-31 | $10.8M | $520,000 | +5.04% |
| Q4 2024 | 2024-12-31 | $21.5M | $10.4M | +93.31% |
| Q3 2024 | 2024-09-30 | $6.6M | −$6.9M | −51.43% |
| Q2 2024 | 2024-06-30 | $8.1M | −$5.0M | −38.37% |
| Q1 2024 | 2024-03-31 | $10.3M | −$1.4M | −11.91% |
| Q4 2023 | 2023-12-31 | $11.1M | $2.3M | +25.58% |
| Q3 2023 | 2023-09-30 | $13.5M | $4.7M | +53.50% |
| Q2 2023 | 2023-06-30 | $13.1M | $4.1M | +44.88% |
| Q1 2023 | 2023-03-31 | $11.7M | $3.2M | +37.66% |
| Q4 2022 | 2022-12-31 | $8.8M | $2.6M | +41.24% |
| Q3 2022 | 2022-09-30 | $8.8M | $184,000 | +2.14% |
| Q2 2022 | 2022-06-30 | $9.1M | −$59,000 | −0.65% |
| Q1 2022 | 2022-03-31 | $8.5M | $1.8M | +26.72% |
| Q4 2021 | 2021-12-31 | $6.3M | $445,000 | +7.66% |
| Q3 2021 | 2021-09-30 | $8.6M | $838,000 | +10.79% |
| Q2 2021 | 2021-06-30 | $9.1M | $3.5M | +61.06% |
| Q1 2021 | 2021-03-31 | $6.7M | $2.1M | +45.64% |
| Q4 2020 | 2020-12-31 | $5.8M | — | — |
| Q3 2020 | 2020-09-30 | $7.8M | $5.7M | +268.72% |
| Q2 2020 | 2020-06-30 | $5.7M | — | — |
| Q1 2020 | 2020-03-31 | $4.6M | — | — |
| Q3 2019 | 2019-09-30 | $2.1M | — | — |
Spruce Biosciences r&d spending trends
Over the last five fiscal years, Spruce Biosciences's r&d spending decreased from $23.9M to $19.5M, a change of −$4.3M. The latest reported quarter, Q2 2026, shows $12.2M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Spruce Biosciences source filings ↗